Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17305337 | 0.88 | MAPT (0.52) | MEN1KMT2APDK2MAPTHTT | |
| SCHEMBL17305174 | 0.87 | LMNA (0.44) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL19601721 | 0.85 | MAPT (0.57) | LGMNALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL17305385 | 0.84 | LGMN (0.53) | LGMNALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL18701232 | 0.84 | NOTUM (0.54) | MAPTPOLBLMNASMN1; SMN2FFAR4 | |
| SCHEMBL19078462 | 0.83 | HPGD (0.58) | LGMNALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL18064904 | 0.83 | LGMN (0.54) | LGMNALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL18914675 | 0.83 | LGMN (0.54) | LGMNALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL29417691 | 0.83 | LGMN (0.54) | LGMNALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL18914688 | 0.83 | ALDH1A1 (0.49) | LGMNALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455226-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3150578-B1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-14 | — | — | EP | disclosed |
| US-10781211-B2 | Spirocycle compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9981960-B2 | Pyrrolidine compound and application as melanocortin receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| WO-2017197192-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| EP-3150578-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015182723-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | 田辺三菱製薬株式会社 | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781211-B2 | Spirocycle compounds and methods of making and using same | ABHD6, ABHD16A, ACSL6 | LGMN 2964/4885ALDH1A1 932/4885MEN1 3674/4885 |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MC1R, MC5R, MC3R | LGMN 4634/4885ALDH1A1 1837/4885MEN1 987/4885 |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, ACSL6 | LGMN 2964/4885ALDH1A1 932/4885MEN1 3674/4885 |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABHD6, ABHD16A, ACSL6 | LGMN 2964/4885ALDH1A1 932/4885MEN1 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.